LFG
VIRX

Larson Financial Group’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Larson Financial Group’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-43
Closed -$2K – 579
2019
Q1 		$2K Hold
43
– – ﹤0.01% 396
2018
Q4 		$1K Buy
+43
New +$1.75K ﹤0.01% 452

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Larson Financial Group's VIRX Position: Q2 2019 in Review

Larson Financial Group sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2019, closing a stake of 43 shares — an estimated $2K sold.

Larson Financial Group first reported a position in VIRX in Q4 2018 and held it in 2 quarters. The position peaked at $2K in Q1 2019. 45 funds tracked by Wall St. Rank hold VIRX as of Q2 2019.

  • Larson Financial Group reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Larson Financial Group sold 43 Viracta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $2K.
  • Larson Financial Group first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Larson Financial Group's Viracta Therapeutics, Inc. Common Stock position peaked at $2K in Q1 2019.
  • 45 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Larson Financial Group's 13F filing for Q2 2019, filed 16 Jul 2019.